New drug delivery technology from Monash pharmacy acquired by Capsugel
A novel drug delivery technology, developed by researchers at the Monash Institute of Pharmaceutical Sciences (MIPS), has been acquired by Capsugel, a global leader in innovative dose-form development.
Monash University and Capsugel announced recently that Capsugel has acquired the intellectual property pertaining to proprietary Ionic Liquid Technology developed by researchers at MIPS led by Professors Chris Porter and Peter Scammells.
The novel technology uses lipid-like counter-ions to transform crystalline drugs into ionic liquids. This leads to significant increases in drug solubility in lipid-based liquid, semi-solid and multiparticulate formulations.
Under the terms of the agreement, the university will transfer its patent application and associated results and know-how to Capsugel, effective immediately. Capsugel will also extend its existing research collaborations with Professors Colin Pouton, Scammells and Porter at MIPS by funding additional research positions to accelerate the Ionic Liquid technology and future drug-delivery projects.
Capsugel has a long history of collaboration with MIPS based researchers in lipid-based drug delivery science. This includes co-founding the Lipid Formulation Classification System (LFCS) Consortium to advance and standardise evaluation protocols for lipid-based drug-delivery systems.
Professor Bill Charman, Director of the Monash Institute of Pharmaceutical Sciences, said the technology license and research collaboration agreement was a further and substantial step in MIPS’ decade-long partnership with Capsugel.
“We are thrilled to partner with Capsugel to advance the development of the Ionic Liquids Technology and to accelerate our current and future collaborative drug-delivery projects,” he said.
Keith Hutchison, PhD, Senior Vice President, Research & Development, Capsugel said, “Our partnership with MIPS demonstrates Capsugel’s commitment to advancing high-caliber science for improved drug delivery and better healthcare solutions.”
“The Ionic Liquids Technology will allow us to significantly increase drug solubility, reduce absorption variability, decrease excipient levels and reduce pill burden. This represents a valuable addition to our capabilities in designing and developing innovative immediate and modified-release dosage forms. Our continuing work with Monash holds great potential for additional drug-delivery innovations in the future.”
Monash University Faculty of Pharmacy and Pharmaceutical Sciences
Monash University is Australia’s largest university and is ranked in the Top 100 World Universities according to the Times Higher Education World University Rankings. The Monash Institute of Pharmaceutical Science (MIPS) is Australia’s largest pharmaceutical sciences research program in translational drug discovery, drug delivery and drug development. Pharmacy and Pharmacology at Monash is ranked number one in the Asia-Pacific and top 10 worldwide (2014 QS World University Rankings).
About Monash University’s Bachelor of Pharmacy
Monash’s Bachelor of Pharmacy program produces graduates with a sound knowledge and understanding of the science, technology and practice behind pharmacy as a profession. It comprises four major areas of study: medicinal chemistry (the chemistry of drugs); pharmacology (the action of drugs); pharmaceutics (the presentation and delivery of drugs); and pharmacy practice (the application of all these to the professional practice of pharmacy).
Program: Bachelor of Pharmacy (BPharm)
Location: Melbourne, Victoria
Semester intake: February
Duration: 4 years
Application deadline: While there is no set application deadline, applicants are strongly encouraged by to submit their applications before the end of September for the February intake.